130 related articles for article (PubMed ID: 26736010)
1. Abrupt Relapse of ALK-Positive Lymphoma after Discontinuation of Crizotinib.
Gambacorti-Passerini C; Mussolin L; Brugieres L
N Engl J Med; 2016 Jan; 374(1):95-6. PubMed ID: 26736010
[No Abstract] [Full Text] [Related]
2. Crizotinib in anaplastic large-cell lymphoma.
Gambacorti-Passerini C; Messa C; Pogliani EM
N Engl J Med; 2011 Feb; 364(8):775-6. PubMed ID: 21345110
[No Abstract] [Full Text] [Related]
3. Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas.
Boi M; Zucca E; Inghirami G; Bertoni F
Br J Haematol; 2015 Mar; 168(6):771-83. PubMed ID: 25559471
[TBL] [Abstract][Full Text] [Related]
4. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors of the anaplastic lymphoma kinase.
Mologni L
Expert Opin Investig Drugs; 2012 Jul; 21(7):985-94. PubMed ID: 22612599
[TBL] [Abstract][Full Text] [Related]
6. Crizotinib in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma in the setting of renal insufficiency: a case report.
Kothari S; Ud-Din N; Lisi M; Coyle T
J Med Case Rep; 2016 Jun; 10():176. PubMed ID: 27301488
[TBL] [Abstract][Full Text] [Related]
7. Trial watch: success for crizotinib in ALK-driven cancer.
Nat Rev Drug Discov; 2010 Dec; 9(12):908. PubMed ID: 21119722
[No Abstract] [Full Text] [Related]
8. Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase-positive lymphoma patients.
Gambacorti Passerini C; Farina F; Stasia A; Redaelli S; Ceccon M; Mologni L; Messa C; Guerra L; Giudici G; Sala E; Mussolin L; Deeren D; King MH; Steurer M; Ordemann R; Cohen AM; Grube M; Bernard L; Chiriano G; Antolini L; Piazza R
J Natl Cancer Inst; 2014 Feb; 106(2):djt378. PubMed ID: 24491302
[TBL] [Abstract][Full Text] [Related]
9. Crizotinib resistance in acute myeloid leukemia with inv(2)(p23q13)/RAN binding protein 2 (RANBP2) anaplastic lymphoma kinase (ALK) fusion and monosomy 7.
Takeoka K; Okumura A; Maesako Y; Akasaka T; Ohno H
Cancer Genet; 2015 Mar; 208(3):85-90. PubMed ID: 25766836
[TBL] [Abstract][Full Text] [Related]
10. Treatment and detection of ALK-rearranged NSCLC.
Peters S; Taron M; Bubendorf L; Blackhall F; Stahel R
Lung Cancer; 2013 Aug; 81(2):145-54. PubMed ID: 23769207
[TBL] [Abstract][Full Text] [Related]
11. Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response.
Wass M; Behlendorf T; Schädlich B; Mottok A; Rosenwald A; Schmoll HJ; Jordan K
Eur J Haematol; 2014 Mar; 92(3):268-70. PubMed ID: 24330038
[No Abstract] [Full Text] [Related]
12. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
[TBL] [Abstract][Full Text] [Related]
14. Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation.
Ordemann R; Stöhlmacher J; Beuthien-Baumann B; Platzek I; van den Hoff J; Kroschinsky F; Middeke JM; Platzbecker U; Zietz C; Bornhäuser M; Ehninger G
Ann Hematol; 2013 Jan; 92(1):125-7. PubMed ID: 22820970
[No Abstract] [Full Text] [Related]
15. Diagnostic and therapeutic issues for patients with advanced non‑small cell lung cancer harboring anaplastic lymphoma kinase rearrangement: European vs. US perspective (review).
Di Maio M; De Marinis F; Hirsch FR; Gridelli C
Int J Oncol; 2014 Aug; 45(2):509-15. PubMed ID: 24859689
[TBL] [Abstract][Full Text] [Related]
16. ALK-targeted therapy for poor-prognosis childhood cancers.
Moreno L
Lancet Oncol; 2013 May; 14(6):439-40. PubMed ID: 23598173
[No Abstract] [Full Text] [Related]
17. Reduction of leukemia cell burden and restoration of normal hematopoiesis at 3 months of crizotinib treatment in RAN-binding protein 2 (RANBP2)-anaplastic lymphoma kinase (ALK) acute myeloid leukemia.
Maesako Y; Okumura A; Takeoka K; Kishimori C; Izumi K; Kamoda Y; Iioka F; Akasaka T; Ohno H
Leukemia; 2014 Sep; 28(9):1935-7. PubMed ID: 24850290
[No Abstract] [Full Text] [Related]
18. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive.
Malik SM; Maher VE; Bijwaard KE; Becker RL; Zhang L; Tang SW; Song P; Liu Q; Marathe A; Gehrke B; Helms W; Hanner D; Justice R; Pazdur R
Clin Cancer Res; 2014 Apr; 20(8):2029-34. PubMed ID: 24573551
[TBL] [Abstract][Full Text] [Related]
19. Crizotinib in the treatment of non--small-cell lung cancer.
Rothschild SI; Gautschi O
Clin Lung Cancer; 2013 Sep; 14(5):473-80. PubMed ID: 23790969
[TBL] [Abstract][Full Text] [Related]
20. Complete Response of Anaplastic Lymphoma Kinase-Mutated Refractory Extranodal Natural Killer/T-Cell Lymphoma to Crizotinib.
Thanarajasingam G; Edell ES; Markovic SM
Mayo Clin Proc; 2016 Sep; 91(9):1319-20. PubMed ID: 27594191
[No Abstract] [Full Text] [Related]
[Next] [New Search]
